These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30446652)

  • 101. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.
    Newton R; Bowler KA; Burns EM; Chapman PJ; Fairweather EE; Fritzl SJR; Goldberg KM; Hamilton NM; Holt SV; Hopkins GV; Jones SD; Jordan AM; Lyons AJ; Nikki March H; McDonald NQ; Maguire LA; Mould DP; Purkiss AG; Small HF; Stowell AIJ; Thomson GJ; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
    Eur J Med Chem; 2016 Apr; 112():20-32. PubMed ID: 26874741
    [TBL] [Abstract][Full Text] [Related]  

  • 102. RET signaling in breast cancer therapeutic resistance and metastasis.
    Pecar G; Liu S; Hooda J; Atkinson JM; Oesterreich S; Lee AV
    Breast Cancer Res; 2023 Mar; 25(1):26. PubMed ID: 36918928
    [TBL] [Abstract][Full Text] [Related]  

  • 103. CCDC6-RET fusion protein regulates Ras/MAPK signaling through the fusion- GRB2-SHC1 signal niche.
    Qiu T; Kong Y; Wei G; Sun K; Wang R; Wang Y; Chen Y; Wang W; Zhang Y; Jiang C; Yang P; Xie T; Chen X
    Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2322359121. PubMed ID: 38805286
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing.
    Yang L; Lee MS; Lu H; Oh DY; Kim YJ; Park D; Park G; Ren X; Bristow CA; Haseley PS; Lee S; Pantazi A; Kucherlapati R; Park WY; Scott KL; Choi YL; Park PJ
    Am J Hum Genet; 2016 May; 98(5):843-856. PubMed ID: 27153396
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells.
    Zhang D; Shi X; Zheng W; Zhang X; Chen Y
    Proteomics Clin Appl; 2024 Jan; 18(1):e2300061. PubMed ID: 37672800
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.
    Morandi A; Isacke CM
    Breast Cancer Res; 2014 Jan; 16(1):301. PubMed ID: 24467886
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
    Moccia M; Yang D; Lakkaniga NR; Frett B; McConnell N; Zhang L; Brescia A; Federico G; Zhang L; Salerno P; Santoro M; Li HY; Carlomagno F
    Sci Rep; 2021 Aug; 11(1):16103. PubMed ID: 34373541
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.
    Griseri P; Garrone O; Lo Sardo A; Monteverde M; Rusmini M; Tonissi F; Merlano M; Bruzzi P; Lo Nigro C; Ceccherini I
    Oncotarget; 2016 May; 7(18):26465-79. PubMed ID: 27034161
    [TBL] [Abstract][Full Text] [Related]  

  • 109. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
    Hayashi T; Odintsov I; Smith RS; Ishizawa K; Liu AJW; Delasos L; Kurzatkowski C; Tai H; Gladstone E; Vojnic M; Kohsaka S; Suzawa K; Liu Z; Kunte S; Mattar MS; Khodos I; Davare MA; Drilon A; Cheng E; Stanchina E; Ladanyi M; Somwar R
    Dis Model Mech; 2020 Dec; 14(2):. PubMed ID: 33318047
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Ret kinase-mediated mechanical induction of colon stem cells by tumor growth pressure stimulates cancer progression in vivo.
    Nguyen Ho-Bouldoires TH; Sollier K; Zamfirov L; Broders-Bondon F; Mitrossilis D; Bermeo S; Guerin CL; Chipont A; Champenois G; Leclère R; André N; Ranno L; Michel A; Ménager C; Meseure D; Demené C; Tanter M; Fernández-Sánchez ME; Farge E
    Commun Biol; 2022 Feb; 5(1):137. PubMed ID: 35177769
    [TBL] [Abstract][Full Text] [Related]  

  • 111. OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma.
    Liu W; Li H; Aerbajinai W; Botos I; Rodgers GP
    Oncogene; 2022 Jan; 41(1):72-82. PubMed ID: 34675408
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.
    Walker TJ; Reyes-Alvarez E; Hyndman BD; Sugiyama MG; Oliveira LCB; Rekab AN; Crupi MJF; Cabral-Dias R; Guo Q; Dahia PLM; Richardson DS; Antonescu CN; Mulligan LM
    Elife; 2024 Apr; 12():. PubMed ID: 38687678
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Genetic fusions favor tumorigenesis through degron loss in oncogenes.
    Liu J; Tokheim C; Lee JD; Gan W; North BJ; Liu XS; Pandolfi PP; Wei W
    Nat Commun; 2021 Nov; 12(1):6704. PubMed ID: 34795215
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.
    Kong Y; Jiang C; Wei G; Sun K; Wang R; Qiu T
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375228
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Intestinal Motility May Not Be Completely Dependent on Epithelial RET Signaling in the Adult Intestine.
    Karkala F; Wang M; Alves MM; Parikh K
    Gastroenterology; 2024 Aug; 167(3):629-630. PubMed ID: 38593923
    [No Abstract]   [Full Text] [Related]  

  • 116. Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase.
    Maturi A; Sastry KNV; Kumar S; Pogaku V; Kwon HJ; Ahn SM; Kim MH
    ACS Med Chem Lett; 2024 Sep; 15(9):1566-1574. PubMed ID: 39291010
    [TBL] [Abstract][Full Text] [Related]  

  • 117. RET signalling controls gut motility.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2024 Feb; 21(2):71. PubMed ID: 38066101
    [No Abstract]   [Full Text] [Related]  

  • 118.
    Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
    Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
    Pahuja KB; Nguyen TT; Jaiswal BS; Prabhash K; Thaker TM; Senger K; Chaudhuri S; Kljavin NM; Antony A; Phalke S; Kumar P; Mravic M; Stawiski EW; Vargas D; Durinck S; Gupta R; Khanna-Gupta A; Trabucco SE; Sokol ES; Hartmaier RJ; Singh A; Chougule A; Trivedi V; Dutt A; Patil V; Joshi A; Noronha V; Ziai J; Banavali SD; Ramprasad V; DeGrado WF; Bueno R; Jura N; Seshagiri S
    Cancer Cell; 2018 Nov; 34(5):792-806.e5. PubMed ID: 30449325
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
    Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
    Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.